Rutin for Health & Longevity - Quick Reference Sheet

Rutin for Health & Longevity

Created on 10/09/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Sonnet 5.5 – Audit

Rutin, a plant compound (quercetin attached to a sugar), is sold as an oral supplement in the hope of supporting health and longevity. Most human evidence concerns chemically modified relatives used for leg-vein complaints. For rutin itself, a few small trials on blood glucose, blood fats and blood pressure show mixed results; lifespan findings come from animals only. Benefit is plausible but largely unproven; risks are mostly mild. (Full Review)

Protocol

Metabolic trial regimens
500 mg/day
3 months in type 2 diabetes; 12 weeks in overweight adults; 6 weeks in healthy women
Competing forms
Doses not interchangeable
Plain rutin 500 mg/day; monoglucosyl rutin 200 or 400 mg/day; rutin 180 mg/day with vitamin C 480 mg/day; none is the default
Time of day
No trial tested timing
With a fat-containing meal is common practice
Time to effect
Metabolic effects in type 2 diabetes
3 months
Assessed at 3 months at 500 mg/day
Leg swelling and symptoms
Days to 8 weeks
Hydroxyethylrutosides (rutin derivatives) in small controlled studies
Metabolic effects without diabetes
Absent at 12 weeks
Overweight adults without diabetes

Benefits

Contraindications
  • People allergic to rutin, quercetin or any ingredient of the specific product
  • Women in early pregnancy (theoretical for rutin)
  • Transplant recipients taking cyclosporine or tacrolimus (theoretical)
  • Antivirals such as nirmatrelvir with ritonavir (theoretical)
Key Interactions
  • CYP3A substrates (midazolam, atorvastatin, simvastatin): caution (theoretical for rutin)
  • OATP1B1 (liver uptake transporter) substrates (pravastatin, rosuvastatin): caution (theoretical for rutin)
  • Glucose-lowering medicines (metformin, glipizide, insulin): monitor (theoretical)
  • P-glycoprotein (drug-efflux pump) substrates (fexofenadine, talinolol): caution (theoretical for rutin)
  • CYP2E1 substrates (chlorzoxazone): caution (theoretical for rutin)
  • Antihypertensive medicines (amlodipine, lisinopril, losartan): monitor (theoretical)
  • Anticoagulants and antiplatelet drugs (warfarin, apixaban, clopidogrel): monitor (theoretical)
  • Chemotherapy (cisplatin, gemcitabine): caution (theoretical)
  • Over-the-counter NSAIDs (diclofenac, aspirin, ibuprofen): monitor (theoretical)
  • Other flavonoids (quercetin, diosmin, hesperidin): caution (theoretical)
  • Glucose-lowering supplements (berberine, chromium): monitor (theoretical)
  • Antiplatelet supplements (fish oil, ginkgo, garlic): caution (theoretical)
  • Iron supplements: monitor (theoretical)
  • Alcohol: caution (theoretical)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Gastrointestinal and other adverse events; Altered exposure to co-administered medicines; Congenital anomalies after early-pregnancy exposure
  • Speculative: Dose reversal at high exposures; Reduced iron availability through chelation; Allergic reactions; Hormone-sensitive cancer and lactation precautions; Added bleeding tendency with clot-preventing medicines

Monitoring

Marker Target Why
Hemoglobin A1c 4.0–5.6% (standard reference range); no rutin-specific target, so track change from own baseline Marker rutin is expected to change (type 2 diabetes trial)
Fasting glucose 70–99 mg/dL (3.9–5.5 mmol/L) (standard reference range); no rutin-specific target, so track change from own baseline Marker rutin is expected to change (type 2 diabetes trial)
LDL cholesterol, HDL cholesterol and total cholesterol No established target; track change from own baseline Markers rutin is expected to change (type 2 diabetes trial)
Blood pressure No established target; track change from own baseline Marker rutin is expected to change (type 2 diabetes trial); safety check with antihypertensive medicines (theoretical)
Immunosuppressant trough level (cyclosporine, tacrolimus) No established target; track change from own baseline Safety check (theoretical): lowered cyclosporine exposure in rats
INR 0.8–1.2 in people not taking anticoagulants (standard reference range) Safety check (theoretical): possible added bleeding tendency

Cadence: Metabolic markers rechecked at 3 months, then every 6–12 months; medicine levels or clotting tests rechecked within weeks of starting or stopping (common practice)

Qualitative Assessment

  • Leg heaviness and swelling, when used for venous symptoms
  • Digestive tolerability
  • Energy and general well-being